Conclusion: Starting BIAsp 30 in people with type 2 diabetes in the A 1 chieve study was found to be cost-effective across all country settings at 1-and 30-year time horizons, and usefully increased predicted life expectancy.
1.

Introduction
The worldwide prevalence of diabetes is steadily increasing, and is expected to reach 592 million by 2035 [1] . Global diabetes-related expenditure, estimated at USD548 billion in 2013, is expected to increase to USD627 billion by 2035 [1] . The International Diabetes Federation estimates that 80% of people with diabetes live in low-and middle-income countries where local health-care systems are often not equipped to deal with the economic burden of diabetes [2] . Newly developed countries also have high diabetes prevalence.
In developing and recently developed countries, many people with diabetes are diagnosed late and may already have diabetes-related complications, resulting in significant costs for individuals and families where government-funded healthcare social security is low or absent. People of working age are especially affected, with consequences for the economic potential of the countries [1] . Successful management of diabetes includes control of high glucose levels [2, 3] . However, many people with type 2 diabetes mellitus (T2DM) are not achieving the generally recommended levels for good glycaemic control (HbA 1c < 7.0% [<53 mmol/mol]) [2] [3] [4] [5] .
Analyses of randomised clinical trials (RCTs) [6, 7] and data from non-interventional studies [4, 5, 8] confirm that beginning insulin analogues in people taking glucose-lowering drugs (OGLDs) alone is associated with clinically significant improvements in glucose control while improving quality of life. Furthermore, there is evidence to support biphasic insulin aspart 30 (BIAsp 30) as a cost-effective treatment option in a number of western and developed countries [9] [10] [11] .
Evaluation of how health-care funds should be spent to maximise health benefits requires assessment of the economic impact of diabetes interventions. Because of the progressive nature of diabetes and the complexity of the clinical outcomes, health-economic (HE) data modelling is helpful in estimating the effects of an intervention on health consequences and costs. These models can bring together data from a variety of different sources including RCTs, observational studies, case registries, public health statistics, and quality-of-life surveys, simulating disease progression and related costs through time in a population. In rapidly developing and recently developed countries where health-care costs are diverse, data from observational studies can be of use in HE modelling by reflecting actual outcomes in clinical practice, especially where there is a paucity of RCT data for these populations [12] [13] [14] .
A 1 chieve was a very large observational study conducted in countries across Asia, Africa, Eastern Europe, and Latin America, designed to evaluate the safety and clinical effectiveness of insulin analogues in people with T2DM in clinical practice [4] . It thus provides an opportunity to explore how the insulin analogues performed in diverse, heterogeneous populations and to conduct cost-effectiveness analyses in non-western populations. In turn, this may help the evolution of diabetes guidelines and enable the optimal allocation of scarce health-care resources. Furthermore, the prospective use of the globally validated EQ-5D instrument provides a unique opportunity to base the health-related quality of life (HRQoL) data used as input in the HE model on answers from the same population as the clinical outcomes are observed. The aim of the present analysis is to assess the long-and short-term cost-effectiveness of starting BIAsp 30 in people with T2DM poorly controlled on OGLDs applying the specific EQ-5D and clinical outcome data collected during the A 1 chieve study.
2.
Participants and methods [4, 15] . In summary, data were collected on clinical effectiveness and adverse events at routine clinical visits (baseline, 12 and 24Áweeks). Participants were asked to complete the EQ-5D questionnaire, used for self-assessment of HRQoL, at baseline and week 24 [15] .
Simulation cohort
The cost-effectiveness analysis used clinical data from the A 1 chieve study for the measurement of health outcomes. Data were included for people being treated for diabetes with OGLDs alone at pre-study and starting BIAsp 30 at baseline, in most cases keeping at least part of the OGLD treatment. To secure reliable estimates and for the analysis to be representative for the average population, only countries where more than 100 insulin-naïve people started BIAsp 30 were included. An HbA 1c result at both baseline and end of study was also required. These criteria result in study populations from Saudi Arabia (n = 901), India (n = 7546), and Indonesia (n = 153), and three North African countries grouped together (Algeria, Tunisia, and Morocco; n = 279), analysed using economic data from Algeria. The prevalence of diabetes has risen dramatically in these neighbouring countries in recent years and they have experienced similar rapid economic development and changes in lifestyle that endorse their assignment as a single population, defined specifically by treatment choice, for this analysis [16] . Baseline characteristics of the defined populations, and changes in blood-glucose control, body mass index, plasma lipids, systolic blood pressure, hypoglycaemia, and EQ-5D-based HRQoL are shown in Table 1 .
The clinical and economic costs of starting BIAsp30 (with or without changes to OGLDs) in each country were projected over a 30-year time horizon for the base-case using the IMS CORE Diabetes Model (version 8.5; Basel, Switzerland) [17, 18] . Baseline and clinical data from the A 1 chieve cohorts were used together with economic data including annual diabetes management costs (medications and surveillance tests) and relevant comorbid medical conditions taken from the published literature [19] [20] [21] [22] . The costs of BIAsp30 and OGLDs were sourced from local Novo Nordisk affiliates. Both costs and effects were discounted at an annual rate of 3.0% according to World Health Organization (WHO) guidelines [14] . Background mortality rates for each country were taken from WHO data tables.
A short-term analysis (for the first year after starting BIAsp 30) was conducted using the incremental cost of treatment and the incremental effect on EQ-5D only.
CORE diabetes model
The CORE Diabetes Model is an analysis tool for both type 1 and type 2 diabetes. Independent and non-product-specific, it takes into account costs for diabetes-related therapy (acquisition costs of the insulin) and management (current clinical management activity), and complication costs (including screening and treatment strategies for micro-and macrovascular complications, and treatment practices for end-stage complications). The interactive computer simulation of disease progression is based on a series of interdependent Markov submodels that simulate the progression of diabetesassociated complications. A full description of the models has been previously published [17, 18] . Each of the models applies time, health state, duration of health state, and diabetes typedependent probabilities predominately derived from the published UKPDS, DCCT, and Framingham studies. The reliability of the model has been validated against clinical trial reports [17] . Baseline, clinical, and economic data can be entered by the user, allowing projection of country-specific short-and long-term outcomes and costs. A 1 chieve studyspecific change in EQ-5D HRQoL scores from the participating countries [8] replaced the default CORE values in the current analysis.
Statistics
Non-parametric bootstrapping was used in each simulation (1000 people and 1000 bootstraps per country) to construct confidence intervals around the data [23] . The incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY) was calculated in local currency, USD, and as a fraction of the gross domestic product (GDP) per capita for each country. ICERs reveal the cost per unit of benefit from switching from one treatment to another and GDP data were taken from the World Bank report for 2011 [24] . Costeffectiveness was pre-defined according to the WHO CHOosing Interventions that are Cost-Effective (CHOICE) programme threshold based on GDP per capita [25] . Categorisation by this system defines a health technology to be cost-effective if incremental cost per incremental QALY gained falls between 1.0 and 3.0 times GDP per capita, highly cost-effective if <1.0 GDP per capita, and dominant (i.e., cost-saving) if costs per QALY gained are <0.0. 
A series of sensitivity analyses was performed to examine how robust the findings of the base-case analysis would be if the assumptions made in the model were varied. A sensitivity analysis on the time horizon was performed by extending the time horizon to 50Áyears, ensuring everyone was dead at the end of the study period. The impact of cost changes was examined assuming two self-measured blood glucose (SMBG) strips per day versus zero strips in the base-case; four additional visits to the healthcare practitioner in the first year following starting insulin (first visit to a specialist, others in primary care); two general practitioner visits every year after starting insulin; comparator arm starting BIAsp 30 after 5 years rather than staying on OGLDs indefinitely. The impact of HbA 1c changes was assessed by assuming no change in HbA 1c over time (+0.15%-unit increase in HbA 1c per year used in base-case scenario after first year), the median rather than mean change in HbA 1c , and the HbA 1c treatment effect in the quarter of the population with the smallest change. A further sensitivity analysis used average A 1 chieve EQ-5D data for BIAsp 30 rather than country-specific data. For the 1-year short-term analysis, sensitivity analyses were conducted by adding the cost of monitoring strips and for four general practitioner visits, respectively.
An analysis was also conducted to project the maximum putative cost of treatment that would result in an ICER of three times GDP per capita, i.e., the limit of cost-effectiveness, to assess the room for additional costs not taken into account in the base-case analyses.
Results
3.1.
Life expectancy, diabetes-related complications, costs, and cost-effectiveness The significant improvements in surrogate clinical outcomes following change in therapy to BIAsp 30 AE OGLDs in people with T2DM (Table 1) were associated with projected improvements in life expectancy of 1.9 years in Saudi Arabia, 1.3 years in India, 1.8 years in Indonesia, and 1.5 years in Algeria.
Projected reductions in 30-year incidence of diabetesrelated complications compared with OGLD treatment alone are shown in Table 2 . Expressed as relative risk, the risk of a myocardial infarction event was reduced by 20% (Saudi Arabia), 19% (India), 32% (Indonesia), and 22% (Algeria). The risk of blindness was reduced by 35% in Saudi Arabia and India, 47% in Indonesia, and 33% in Algeria. The risk of dialysis was projected to fall by between 64% (India) and 78% (Indonesia), and the risk of foot ulceration by between 2% (Saudi Arabia) and 23% (Indonesia). The time free of any complication in people with T2DM was greater with BIAsp 30 AE OGLDs compared with OGLD treatment alone; the difference between treatments ranged between a gain of 2.0 years in Indonesia and 0.18 years in Saudi Arabia. Similar trends in delayed onset were observed for other complications ( Table 2 ). The estimated QALY gains were 2.77 for Saudi Arabia, 4.57 for India, 2.73 for Indonesia, and 2.65 for Algeria.
The projected differences in glucose-lowering treatment costs, management costs, complication-related costs, and overall costs after switching therapy from OGLD only to BIAsp 30 AE OGLDs over a 30-year time horizon are shown in Table 3 . While therapy costs were higher with insulin in all countries, and management costs similar, complicationrelated costs were lower. Accordingly, change in overall health-care expenditure ranged from 42% higher in Algeria to 4% lower in Saudi Arabia; India (+30%) and Indonesia (+20%) were intermediate. Expressed in US dollar terms, the discounted average extra cost per person ranged from costsaving in Saudi Arabia to USD165 per year in Algeria (Table 3) .
The long-and short-term cost-effectiveness of starting BIAsp 30 +/AE OGLDs in insulin-naïve people with T2DM from Saudi Arabia, India, Indonesia, and Algeria is shown in Table 4 . Base-case analysis (30 years) showed India, Indonesia, and Algeria to have an ICER per QALY gained of <1.0 GDP per capita (0.25, 0.47, and 0.46, respectively) compared to OGLD therapy, meeting the definition of highly cost-effective. As BIAsp 30 delivered both discounted cost savings and marked improvements in health outcomes in Saudi Arabia, the insulin therapy was cost-saving over OGLDs alone. In the short-term 1-year analysis, ICER per QALY gained after starting BIAsp 30 therapy 
was estimated to be highly cost-effective in Saudi Arabia (0.14 of GDP per capita), India (0.43), and Algeria (0.73), while being cost-effective in Indonesia (1.20 of GDP per capita) ( Table 4) .
Sensitivity analyses
The series of sensitivity analyses revealed that there was little or no impact on ICERs. This was true for extending the time horizon to 50 years, if no deterioration with time in HbA 1c was factored into the model, and if the median HbA 1c treatment effect was used in place of the mean value (Fig. 1) . Similarly, there was little effect of two additional primary care visits in every year following start of BIAsp 30 or if the average global EQ-5D value replaced the country-specific data (Fig. 1) . If BIAsp 30 was begun after 5 years in the OGLD group, but the model still ran for 30 years, the ICERs were projected to change only marginally in Saudi Arabia and were lower than for the base-case analysis in India, Indonesia, and Algeria (Fig. 1) . The results were more sensitive to using the lowest quarter data for the HbA 1c treatment effect and to the inclusion of treatment costs with either additional SMBG strip use or including four additional clinic visits in the first year after the change in therapy. Nevertheless, the predicted outcomes (ICER) were still well within the cost-effective range (ICER < 3.0 ratio to GDP per capita).
The increase in total current costs that would still deliver an ICER of 3.0 GDP/QALY (i.e., which would be on the costeffectiveness limit) was estimated to be 90% for Indonesia, 161% for Algeria, 252% for India, and 435% for Saudi Arabia.
Discussion
This analysis has used country-specific data for healthcare costs, combined with country-specific short-term health 
output data from the large A 1 chieve study, to estimate the long-term (base-case 30 years) costs and health outcomes associated with starting BIAsp 30 with or without OGLDs according to local practice in people with T2DM in routine diabetes care. Although the total population studied in A 1 chieve was large, individual country populations started on this insulin restricted the analysis to four countries (after combining data for Algeria, Morocco, and Tunisia), with large numbers of people from India and Saudi Arabia, and smaller but useful numbers from Algeria and Indonesia. These four ; GDP, gross domestic product; GP, general practitioner; OGLD, oral glucose-lowering drug; QALY, quality-adjusted life-year; SMBG, self-measured blood glucose; T2DM, type 2 diabetes mellitus; ICER, incremental cost-effectiveness ratio.
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'countries' are very different in terms of economic resources, development, and culture, but nevertheless, when adjusted to GDP using the WHO CHOICES criteria, starting insulin therapy with BIAsp 30 was highly cost-effective by the base-case in all of them (Table 4 ). The positive clinical outcomes from these participants in the A 1 chieve study (Table 1. ) are likely to have contributed to this finding, as improved glycaemic control and HRQoL have been associated with reduced health-care costs in adults with diabetes [26, 27] . Due to the chronic nature of diabetes and the severity of associated complications, diabetes is a very costly disease. These costs are not only financial, affecting, directly or indirectly, the individual and their families, in addition to social care. Studies in India indicate that the economic burden of diabetes care on families is rising rapidly, with 85-95% of all healthcare costs being borne by individuals and their families from household income [28, 29] . Taking into consideration that people diagnosed with diabetes can have significantly higher healthcare requirements and expenditures than in the absence of diabetes, the growing prevalence of diabetes will pose tremendous future challenges for low to middle-income countries [30, 31] . In this context, an intervention that can deliver increased life expectancy of >1 year with reduced incidence of diabetes-related complications and delayed onset of these would appear attractive.
As might be expected, costs of treatment, management, and complications were much higher in Saudi Arabia than other counties (and lowest in India) due to the economic circumstances of the country. However, the modelled extra treatment costs of starting BIAsp 30 are largely balanced out by the lower overall complication rates and, therefore, the lower estimated costs of complication management, including specific treatment costs and management costs related to those complications (Table 3 ). This offset effect is not complete, except in Saudi Arabia, largely because the complication costs per se are much lower, expressed in GDP per capita. Nevertheless, the ICERs are still all under a sixth of the WHO threshold for cost-effectiveness in the base-case. While the analysis showed cost savings in Saudi Arabia, this was not driven by differences in modelled outcomes or a larger reduction in outcomes compared to the other countries. Within the limits of the assumptions made, the numbers of people affected by adverse health events were broadly similar between the four countries, as were the improvements expected in clinical outcomes often associated with starting insulin ( Table 2) .
The Indonesian and Algerian data are intermediate compared with Saudi Arabia and India, Indonesian and Algerian estimates for diabetes as a proportion of total health-care expenditure being 7% and 11% of total in 2010 [32] . Both of these A 1 chieve sub-populations reported relatively poor glycaemic control at baseline (mean HbA 1c 10.1%; 86.9 [18.6] mmol/mol) and thus had an opportunity for larger improvements at 24 weeks (À2.9%-units in Indonesia; À2.6%-units in Algeria). As HbA 1c is a major driver of reduced complications in diabetes, and thus in the CORE Diabetes Model, the proportionately high reductions in the cost of complications are estimated (Table 2 and 3) , and the ICER associated with the intervention is highly cost-effective in GDP terms here too.
The results of the CORE modelling do not support the view, mostly from developed nations, that the costs of diabetes are driven overall by the costs of managing its complications [33] . Rather, in this analysis, they are close to being in balance. This disparity is perhaps explained by our population having T2DM and being rather older, such that death from other comorbidities restricts the opportunity to suffer some vascular complications and to incur their costs over many years. The problem remains that, for health authorities or individuals alike, the increased cost of effective diabetes management does have to be accepted to gain savings or potential health benefits in the longer term. However, in this analysis, the short-term model, for the first year after starting BIAsp 30, based only on the incremental cost of treatment and the incremental effect on EQ-5D, indicated that an early benefit could be possible.
A number of studies have examined long-term clinical and economic outcomes after starting BIAsp 30 in western nations and in South Korea [9, 10, [34] [35] [36] , finding it to be cost-effective. Palmer and colleagues, using data from the PRESENT study, examined the cost-effectiveness of converting from biphasic human insulin to BIAsp 30 in China. They found that the increased costs are largely offset by reduction in complication costs, but with improved outcomes giving a high level of costeffectiveness [37] . Also of partial relevance to the current study is a cost-effectiveness analysis of conversion from biphasic human insulin to BIAsp 30 in Saudi Arabia, again based on data from the PRESENT study, which found cost savings with improved outcomes (dominance) when using the CORE Diabetes Model [28] . As well as extending this last analysis to the more typical situation of people starting insulin, in the current study the global range of HE analysis is much extended by the modelling for other countries.
The strengths and weaknesses of the underlying A 1 chieve observational study data have been discussed elsewhere, limitations including the relatively short observation period, the likelihood of lifestyle change accompanying the starting of insulin therapy, and the possibility of regression to the mean in core surrogate outcomes such as HbA 1c [4, 15] . Being an observational study, there is no control group, so we can only make HE comparisons against baseline therapy. While the intervention was still cost-effective using only HRQoL data over 1 year, it could be argued that our other sensitivity analysis, where all participants were converted to insulin at 5 years, modelled an unacceptable delay in starting insulin. The cost-effectiveness evaluations used here carry other uncertainties, such as the relevance of the underlying equations based on studies like UKPDS and the Framingham Heart Study to the populations studied in A 1 chieve. However the IMS CORE Diabetes Model has been validated against a number of epidemiological and clinical studies, and country-specific epidemiological data. Furthermore, we have performed a number of sensitivity analyses, including testing fundamental assumptions such as continued deterioration with time, using a conservative measure of HbA 1c change, and modelling different time horizons (Fig. 1) . None of these markedly affect the cost-effectiveness. The finding that the 1-year estimate, using only first-year costs and improvement in health utility based on the EQ-5D data, was also cost-effective perhaps indicates that the improvement in HRQoL makes a large contribution to the model outputs, thus reducing the impact of longer-term gains and costs. The sensitivity analysis that otherwise most changed the ICERs was increase in use of SMBG strips, although, even here, all ICERs remained below the cost-ineffectiveness threshold.
Some uncertainties remain around health-care costs. While some were obtained from published and official sources for each country, local diabetes specialists were requested to provide values when no published data were available. Although consensus of up to three specialists was used to attempt to reduce error, some bias is inevitable. In addition, we are not able to account for changes in adherence to injection therapy in the longer term, nor rising insulin dose (and thus insulin costs) with time. For this reason, in the sensitivity analyses we explored the increase in potential overall costs that would still allow the intervention to be costeffective at an ICER of 3.0 times GDP per capita, finding markedly higher incremental costs would be needed, leaving room for adding to the treatment costs over time.
To conclude, with the worldwide prevalence of diabetes steadily increasing and placing ever greater demand on national healthcare expenditure, policymakers need information not only on the safety and effectiveness of an intervention but also on whether it provides good value for money in relation to the cost of treatment. Using clinical data from the A 1 chieve observational study, analysed using the IMS CORE Diabetes Model, our findings indicate that starting insulin therapy with BIAsp 30 in people with poorly controlled T2DM on OGLDs alone is considered to be a highly cost-effective intervention in India, Indonesia, Algeria, and Saudi Arabia. The findings are robust, being reproduced across a number of sensitivity analyses.
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